Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model

Rilotumumab inhibited 18 F-FDG and 18 F-FLT accumulation as early as 2 and 4 days after treatment, respectively, in a mouse tumor model. Further studies to evaluate 18 F-FDG PET imaging as an early tumor response marker for rilotumumab are warranted. Rilotumumab is currently being tested in patients with MET-positive, advanced gastric and gastroesophageal cancer.